Press Release December 8, 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Acarix' share issue well oversubscribed in connection with the initial public offering on Nasdaq First North Premier in Stockholm
Acarix AB ("Acarix" or the "Company") is pleased to announce that it has successfully raised SEK 140 million before transaction costs through a well-oversubscribed share issue in connection with the initial public offering listing on Nasdaq First North Premier (the "Offering"). The Offering was directed to institutional and professional investors as well as to the public in Sweden and Denmark. Due to the large interest, allotment of new shares has been made to around 1,200 new shareholders among 3,000 applicants.
First day of trading of the Company's shares on Nasdaq First North Premier in Stockholm is expected to be December 19, 2016.
Acarix is a Swedish/Danish commercial stage medical device company, specialised in non-invasive, non-radiation acoustic rule-out of Coronary Artery Disease (CAD). The funds raised will primarily be used to execute the Company's commercialization strategy and anticipated launch in Q2, 2017, with initial focus on Germany, UK, Sweden and Denmark for the already CE-marked CADScor®System.
The subscription period for Acarix' Offering expired on December 7, 2016. Already before the subscription period began, a number of existing and new investors, including Puhua Jingxin Guzhou Health Management Partnership, the Bank of Åland's Fund Management Division, Ålandsbanken Abp, Sverker Martin-Löf, Carl-Olof By, and Rolf Börjesson through the company Industrial Development Partners AB, and Lars Holmqvist, former CEO of Dako and later Senior Vice President of Agilent, had committed to subscribe for shares in the Offering totalling just over SEK 120 million or approximately 86 per cent of the Offering. These investors were then given priority when shares were allocated. However, the overall goal of the Offering remained to obtain a broad distribution of shares among the public in Sweden and Denmark in order to allow regular and liquid trading of Acarix' shares on Nasdaq First North Premier.
Vator Securities acted as global co-ordinator and sole bookrunner in the initial public offering.
After the new share issue has been registered at Bolagsverket (the Swedish Companies Registration Office), the total number of shares in Acarix will increase by 7,960,000 to 23,027,376 representing an increase of the share capital and votes of 53 per cent.
Advisors
Vator Securities is the financial advisor and Baker & McKenzie is the legal advisor to the Company in connection with the new share issue and initial public offering on Nasdaq First North Premier. Wildeco is the Certified Advisor to the Company.
For more information, please contact:
Søren Rysholt Christiansen, CEO, Acarix
E-mail: dksrc@acarix.com
Phone: +45 2777 1112
Notes to editors:
Acarix , CADScor®System and cardiac sound measurement
Acarix was established in 2009 as a spinout company from Coloplast A/S. Since 2010 key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK) have financed the development of the company and supported it towards market introduction. While some founders remain in the company, Acarix has attracted a highly experienced management team who have held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.
Acarix' CADScor®System is based on pioneering research at Aalborg University. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen.
The CADScor®System contains the necessary electronics to instruct professionals during use and guide the patient through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the CADScor® sensor to a fixed position above the heart during the recording.
The software embedded in The Acarix CADScor®System ensures that adequate recording conditions are controlled at every examination, whether performing your examinations in a quiet clinical settings or at busy GP clinics, at high altitudes (>95% coverage) or on the move.
The CADScor®System is CE Marked (by TÜV in 2015) and due for commercial launch in 2017.
See more at www.acarix.com.
Important information
This announcement is not and does not form a part of any offer for sale of securities. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Hong Kong, Japan, South Africa or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement
have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive"). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.
This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.
Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe," "expect," "anticipate," "intends," "estimate," "will," "may," "continue," "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward- looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.
